Noureddin M, Harrison SA, Loomba R, Alkhouri N, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025 Nov 11:S0140-6736(25)02114-2. doi: 10.1016/S0140-6736(25)02114.
PMID: 41237796